Innovation & Access for Neglected Populations

Key Challenges & Perspectives for Latin America

Dr Joel Keravec, Latin America Executive Director



Latin America Landscape

Social inequalities \rightarrow Health Access inequalities

- 34% residents live in poverty, with more than 12% living in extreme poverty
- 125 M out of 580 M no access to health services

Considerable disparities in health & social devpt indicators

- Persistence of high maternal and infant mortality rates, diarrheal and respiratory diseases in low resources settings
- Drug resistant infectious agents emergence (MDR-TB)
- Inadequate food, drug safety system & sanitation
- Violence undermines well-being and security









Latin America & the double burden of diseases Infectious and Non Communicable Diseases represent new challenges







- Expansion of people moving from urban to metropolitan areas: Deforestation & exposure to vectors previously sylvatic
- Urbanization > 78% => changes in disease epidemiology patterns: Chagas, Leishmaniosis transmission and Malaria in urban/periurban areas
- Emerging and re-emerging conditions such as arbovirus; Zika, Dengue, Chikungunha, Yellow Fever ...
- Emerging Non Communicable & Chronic diseases (Hypertension, cancer, chronic respiratory diseases, diabetes ...)
- NCDs = 55% of the disability-adjusted life-years (DALYs), communicable, maternal, perinatal and nutritional conditions (27%) and injuries (18%)

Fragile health systems need to adjust to new complexities & increasing healthcare costs



R&D Landscape: Overview of challenges & opportunities


- Brazil, Argentina and Mexico leaders in # of clinical trials
 - Predominance of Phase 3 vs Phase 1 trials
 - Nearly 2/3 are phase 3 trials
 - 2,4% are phase 1 trials
 - Significant differences in regulatory requirements & slow pace of harmonization ("convergency")
 - Fiocruz announced accelerated clinical trials process for Zika ..
- Pharmaceutical industries responsible for 7 out of 10 studies conducted across the region.
- But in Brazil, ~40% of studies conducted by universities, public institutions or other independent researchers
- Increasing number of well-qualified investigators:
 - 110% increase of # of journal articles by in the last 10 years as compared to 15-50% in the US and Europe
 - On going capacity-building



1948 clinical trials on-going in LA



Since 2003 DNDi LA is supported by a diverse & complementary network



Beyond 2016, perspectives for expansion of DNDi activities


Legal entities in Brazil, Argentina & Colombia




- Focus on new treatments for Chagas & Leishmaniosis
- Screening & Lead Optimization
- New Business Plan
 - Hep C, Mycetoma,
 - Antimicrobial Resistance
- Expand Activities in Chile, Venezuela, Guatemala, Honduras, El Salvador...
- Chagas & Leish Access Plans
- Strategic surveillance on other emerging challenges



DND*i* LATAM Regional Office Portfolio





Chagas Disease: clinical trials in the region (1)

The Gap

Treatment for Chronic and Acute phases, to be used in all regions, with a good safety profile, short treatment duration (< 30 days)

E1224 trial (phase 2, Proof of Concept)

- DNDi-CH-E1224-001 / NCT01489228
- Bolivia, 2011 2013 (Awarded DNDi Project of the Year)

Drug-drug Interaction (phase 1 trial)

- Combination between E1224 and Benznidazole
- Argentina, 2014





Chagas Disease: clinical trials in the region (2)

The Gap

Treatment for Chronic and Acute phases, to be used in all regions, with a good safety profile, short treatment duration (< 30 days)

FEXI Trial (phase 2, Proof of Concept)

- Clinical study report by end June 2016
- Bolivia 2014-2016

BENDITA Trial (phase 2, Proof of Concept)

- Benznidazol New improved treatments and associations
- Bolivia, Argentina and Spain
- Expected enrolment starting September 2016





Cutaneous leishmaniasis: clinical trials in the region

The Gap

Topical & oral drugs, safe, effective against all forms of CL, with superior cosmetic results, at low-cost and easy to use

Anfoleish - Phase Ib/II (Colombia)

- Enrolment completed Nov 2015
- Final report expected September 2016.

Combination thermoterapy + miltefosine - Phase II (Peru, Colombia)

- Approvals from regulatory authorities by Q3-2016.
- Trial start expected September 2016.





HAT



Colombia

FOR

De

Guatemala / Honduras

Equador

Bolivia

Chile

gentina

Venezuela

Brazil

Paraguay

Countries highlighted on the map represe Chagas disease-ende Latin American countrie

platform members. M

this map by

Uruguay



A Key Role for Regional Disease Platforms

Defining patient needs and Target Product Profile (TPP) Streng^thening local capacities Conducting clinical trials (Phase II/III studies)

Facilitating Registration of new therapies

Accelerating implementation of new therapies, ensure therapies reach patients

Uganda

Sudar

Ethiop

LEISHMANIASIS

recelets Network of Investigators and Collaborators in Leishmaniasis

UATEMALA

COLO

PER

PANAM


LEISHMANIASIS



WATER.

U ASHEND

CHAGAS




Improve evaluation and delivery of new treatments across the region

Chagas Clinical Research Platform (CCRP)

- Since 2009, a network of health agencies and scientists in the Americas and around the world.
- Annual meetings, trainings, standardization of protocols, regulatory aspects, newsletter publications and integration of ethical principles.


Main activities:

- Identify and/ map gaps in Chagas R&D
- Conduct capacity building & training to support clinical trials
- Strengthen CCRP in endemic and non-endemic countries
- Support activities for to scale up of diagnosis & treatment working closely with policy makers and other stakeholders



DNDi

Out of 150-180 million people suffer from Hepatitis C 10 million live in Latin America



85% of HCV infected people live in low- and middle-income countries




Generic licensing has created gaps for access in high-HCV burden middle-income countries, but there is an opportunity to change the current paradigm in Latin America

Strengths of region

- Strong civil society with advocacy capacity
- Prevalent genotypes (1 and 3) less challenging to treat
- Local and robust manufacturing capacity
- Overall research capacity to conduct trials
- IP aspects:
 - Ravidasvir non exclusive license for DNDi in LA
 - but sofosbuvir already strategically patented in some countries

DNDi license with alternate treatments for HCV





Chagas: An old public health problem requiring innovative solutions...

- 6 million cases in Latin America
- Around 10.000
 deaths/year
- Globally the economic burden is around U\$ 1 billion
- Less than 1% of Chagas infected individuals has access to treatment





Chagas Access Challenges: How to address this major access gap?

- Despite some advances in the Chagas landscape, no significant changes in access occurred.
- Major gaps still remain between the estimates of the number of people living with Chagas disease and those actually diagnosed and receiving treatment
- DNDi is focusing on developing NCE + New Access Strategies:
 - On-going pilot projects
 - Advocacy campaigns with the Global Chagas Coalition and other partners
 - Partnership models







Towards a Comprehensive Chagas Access Plan: A Joint Initiative of DNDi, Chemo Group/FMS





DND*i*, Mundo Sano and Chemo team up to register benznidazole in US and Latin America

Plans will boost access to Chagas treatment throughout Americas

- to register adult (100mg) and paediatric (12.5mg) benznidazole (BZN) with the US FDA, as well as in Mexico, Colombia and other LA endemic countries
- to ensure sustainable access to benznidazole
- to develop a far reaching access plan in the region, in consultation with partners









Developing a pragmatic approach for interventions : from production challenges to a fully functional pharmaceutical system for Access


The Pharmaceutical Management Framework

Management Support Organization and Management Financing **Information Management** Human Resources · Program planning and Pharmaceutical financing strategies. Information-based decision Personnel management implementation approaches including revolving funds Preservice education making · Program monitoring and Analyzing and controlling expenditures Pharmaceutical management Continuing education · Financial planning and management evaluation information systems In-service training Community participation Donor financing Indicator-based monitoring Selection Marketing approval/registration Use Selection · Therapeutic formularies and · Drug information services essential medicines lists Rational prescribing Standard treatment guidelines Use of antimicrobial resistance data Management Procurement Drug use evaluation Procurement Use Support Good dispensing practices Morbidity vs. consumption Patient information/counseling quantification Behavior change strategies Tendering and contracting Curriculum reform Quality assurance and supplier pregualification Distribution Supplier performance Distribution monitoring and evaluation Central medical stores vs. Price monitoring alternative models Pooled procurement/group Policy, Law, & Regulation Vertical vs. integrated purchasing programs Donor coordination Inventory management Medicine donation guidelines Kit system Policy, Law, and Regulation Policies Pharmaceutical Laws and Regulations Generics policies Accreditation/licensing (hospitals, Decentralization

- Use of private services
- Integration of services/supply systems
- Availability by level of care

- pharmacies, providers)
- Procurement laws
- · Pharmacopeial standards
- Pharmacy benefits

Working towards a renewed Access Vision & Innovative Strategies for Chagas with partners : enabling a paradigm shift



Source / southern cone inititative: : A. Moncayo : Chagas Disease: Current Epidemiological Trends after the Interruption of Vectorial and Transfusional Transmission in the Southern Cone Countries "incidence of new infections by T. cruzi in the whole continent has decreased by 70%"



Concluding Remarks: How to build together a strong regional agenda for Innovation & Access



Capacities, willingness, commitments are there:

Elimination of some NTDs in Colombia or Mexico

Alliance for a joint effort to the crisis of Zika & regional research collaboration

New initiatives: Lead Optimization Initiative

(LOLA) , GARD....

Platforms, Networks Partners, Academia

Multi-lateral organizations & Regional Mechanisms

Funding Mechanisms

DNDi is a living laboratory: a rich think tank & catalyst in action for change : not just in what we do but how we do it:

- Strengthening regional capacity for R&D
- Promote evidence based policy changes
- Advocate for new models & bring neglected populations to high level agenda
- What we can learn & share with our partners to develop creative solutions
- => Link global ideas & translate models with interventions at local levels & channels for access

=> How local levels can nurture global health debates and new ideas to demonstrate & promote sustainable changes



Give neglected patients a voice. They exist and must be heard. Thank you. Gracias Obrigado

